MedTrace Logo

EDP167 in Healthy Volunteers and Subjects With Mild Dyslipidemia

NCT07412080 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-02-17

No results posted yet for this study

Summary

EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting ANGPTL3, which may bring benefits for patients with dyslipidemia conditions. This is the first in human study of EDP167 in health volunteers and subjects with mild dyslipidemia to evaluate the safety and PK/PD profiles of EDP167.

Conditions

  • Healthy Adult Male and Female Volunteers
  • Mild Dyslipidemia

Interventions

DRUG

EDP167

EDP167 sc injection

DRUG

Placebo

Sterile normal saline (0.9% NaCl) sc injection

Sponsors & Collaborators

  • Eddingpharm (Zhuhai) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2025-12-12
Completion
2025-12-12

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07412080 on ClinicalTrials.gov